| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Duquesne Family Office · Stanley Druckenmiller | $864.9M | 16.6% | 3.19M | +4.0% | Q2 2026 |
| Coatue Management · Philippe Laffont | $680.0M | 1.40% | 2.51M | −1.4% | Q2 2026 |
| Maverick Capital · Lee Ainslie | $368.3M | 3.25% | 1.36M | +16% | Q2 2026 |
| ARK Investment Management · Cathie Wood | $187.0M | 1.21% | 688.86K | +0.7% | Q2 2026 |
| Viking Global · Andreas Halvorsen | $106.1M | 0.30% | 390.69K | New | Q2 2026 |
| Bridgewater Associates · Ray Dalio | $1.7M | 0.01% | 6.14K | −76% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Josh Gottheimer NJ05 | 2 | 1 | +$8.0K | Bought Sep 22, 25 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Sep 22, 25 | Josh Gottheimer NJ05 | Joint | Buy | $1,001 - $15,000 | Oct 15, 25 (23d) | |
| Aug 22, 25 | Josh Gottheimer NJ05 | Joint | Buy | $1,001 - $15,000 | Sep 5, 25 (14d) | |
| Jul 22, 25 | Josh Gottheimer NJ05 | Joint | Sell (part) | $1,001 - $15,000 | Aug 11, 25 (20d) |
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Rabinowitz MatthewOfficer and Director | Sale at price 328.09 - 351.24 per share. | 102K | $34.80M |
| Sep 10, 2026 | Rabinowitz MatthewOfficer and Director | Sale at price 325.01 - 329.62 per share. | 50K | $16.40M |
| Sep 1, 2026 | Moshkevich SolomonOfficer | Sale at price 319.76 - 326.89 per share. | 18.2K | $5.92M |
| Aug 31, 2026 | Chapman Steven LeonardChief Executive Officer | Sale at price 320.99 per share. | 1.7K | $545.04K |
| Aug 9, 2026 | Fesko JohnPresident | Sale at price 321.53 per share. | 6.5K | $2.10M |
| Aug 9, 2026 | Sheena JonathanDirector | Sale at price 325.32 per share. | 6K | $1.95M |
| Aug 6, 2026 | Sheena JonathanDirector | Sale at price 308.40 - 320.90 per share. | 9.2K | $2.89M |
| Aug 6, 2026 | Rabinowitz MatthewOfficer and Director | Sale at price 320.90 per share. | 2K | $641.80K |
| Aug 5, 2026 | Fesko JohnPresident | Stock Award(Grant) at price 0.00 per share. | 20K | — |
| Aug 3, 2026 | Brophy Michael BurkesChief Financial Officer | Sale at price 267.99 - 274.22 per share. | 795 | $216.03K |
| Aug 2, 2026 | Rabinowitz Daniel AOfficer | Sale at price 267.99 per share. | 334 | $89.51K |
| Aug 2, 2026 | Fesko JohnPresident | Sale at price 267.99 per share. | 295 | $79.06K |
| Aug 2, 2026 | Moshkevich SolomonOfficer | Sale at price 259.98 - 268.70 per share. | 3.4K | $905.63K |
| Aug 2, 2026 | Sheena JonathanDirector | Sale at price 267.99 per share. | 109 | $29.21K |
| Aug 2, 2026 | Rabinowitz MatthewOfficer and Director | Sale at price 267.99 per share. | 731 | $195.90K |
| Aug 2, 2026 | Chapman Steven LeonardChief Executive Officer | Sale at price 259.98 - 268.22 per share. | 3.1K | $819.43K |
| Jul 28, 2026 | Brophy Michael BurkesChief Financial Officer | Sale at price 249.38 - 260.49 per share. | 5.1K | $1.28M |
| Jul 27, 2026 | Rabinowitz Daniel AOfficer | Sale at price 254.07 - 260.49 per share. | 1.9K | $485.11K |
| Jul 27, 2026 | Fesko JohnPresident | Sale at price 254.07 - 260.49 per share. | 1.7K | $440.24K |
| Jul 27, 2026 | Moshkevich SolomonOfficer | Sale at price 254.07 - 260.49 per share. | 2.2K | $569.00K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.9 | -10.0 | -3.9 | 3.1 | 8.3 | 21.5 | -1.4 | 20.2 | 28.4 | -6.5 | +68.7% | ||
| 2025 | 11.8 | -12.1 | -9.1 | 6.7 | 4.5 | 7.1 | -20.9 | 25.9 | -4.3 | 23.6 | 20.0 | -4.1 | +44.7% |
| 2024 | 5.3 | 31.2 | 5.7 | 1.6 | 14.7 | 1.7 | -5.4 | 15.5 | 7.3 | -4.7 | 38.7 | -5.7 | +152.7% |
| 2023 | 6.9 | 13.1 | 14.4 | -8.6 | -7.1 | 3.3 | -7.1 | 29.9 | -24.7 | -10.8 | 41.8 | 12.0 | +55.9% |
| 2022 | -24.3 | -6.9 | -38.1 | -13.7 | 4.5 | -3.4 | 32.6 | 4.8 | -11.0 | 7.2 | -12.4 | -2.3 | −57.0% |
| 2021 | 7.2 | 8.9 | -12.5 | 8.4 | -14.4 | 20.6 | 0.9 | 3.4 | -5.9 | 2.8 | -20.2 | 2.1 | −6.2% |
| 2020 | 3.9 | 8.3 | -21.2 | 24.0 | 18.4 | 13.7 | -3.7 | 32.7 | 13.4 | -6.9 | 31.2 | 12.7 | +195.4% |
| 2019 | -2.7 | 16.6 | 30.2 | -7.3 | 19.8 | 20.4 | 0.0 | 19.5 | -0.5 | 17.4 | -5.3 | -7.7 | +141.3% |
| 2018 | 15.8 | -13.5 | 3.0 | 20.1 | 4.8 | 61.4 | 22.0 | 20.4 | -13.4 | -8.3 | -21.1 | -19.4 | +55.3% |
| 2017 | -23.5 | 6.7 | -7.2 | 2.0 | 13.1 | 6.1 | -25.7 | 53.0 | 4.4 | -14.7 | -11.5 | -7.6 | −23.2% |
| 2016 | -20.8 | -21.1 | 41.0 | 3.2 | 40.4 | -12.5 | 8.6 | -24.0 | 11.7 | -23.7 | 41.5 | -2.4 | +8.4% |
| 2015 | -12.5 | -31.4 | -24.0 | 7.8 | 21.5 | −40.3% |
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Buy / hold / sell counts